CD8A and neoplasm: Murine breast cancer and pancreatic tumor models showed that entinostat combined with anti-PD-1 therapy or anti-CTLA-4 therapy significantly alleviates MDSCs-induced immunosuppression, increases activated granzyme-B-producing CD8+ T effector cell infiltration, significantly improving tumor-free survival (Christmas et al., 2018).